publication date: Jul. 11, 2014
NCI took another step toward adopting a new formula for determining the size of cancer center support grants, with the National Cancer Advisory Board accepting a report from a working group that has been working on the problem since the fall of 2012.
The schema proposed by the working group was accepted by the advisory board at its meeting June 23. It recommends broad organizing principles rather than specific numbers.
|After the Plenary|
Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant
An article in the June 6 issue of The Cancer Letter described plenary presentations at ASCO 2014. One presentation was the adjuvant breast cancer clinical trial ALTTO in HER2-positive disease, which “was chosen [for the plenary session] because it addressed the reliability of pathological complete response as a surrogate for patient benefit.”
George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer
As always, I both enjoyed and learned something interesting from Dr. Don Berry, one of the great biostatisticians of our era. I find, reading his analysis of ALTTO and NeoALTTO, much that I agree with. I am certainly no statistician, and must bow to his statistical analysis of ALTTO and NeoALTTO. And yet at the same time I think it misses the point. So I will beg to differ.
Also: Don Berry’s Rejoinder
|AACR Changes Its Logo— For the Fifth Time Since 2000|
The American Association for Cancer Research ushered in the year 2000 with a round logo that combined the lamp of knowledge with a map of the Americas and an aspirational slogan in Latin.
The 26-year-old logo gave way to one that looked more corporate. However, AACR didn’t stop at just one redesign. It changed the logo four more times.
|NIH Funding Opportunity |
Outstanding Investigator Award In Cancer Research Available
The NIH has published a funding opportunity announcement for the Outstanding Investigator Award in any area of cancer research.
Three appointed to leadership positions at St. Jude
Duke’s Amy Abernethy named chief medical officer at Flatiron Health
William Hogan joins University of Florida as director of bioinformatics
J. Alan Diehl named associate director of basic sciences at MUSC
Vincent O’Neill named chief medical officer of Exosome Diagnostics
Joseph Haywood named president of FASEB
Thomas Jefferson University receives $110 million gift
Stand Up to Cancer Canada launched
Bristol-Myers Squibb announces collaboration with Duke University
Pew Charitable Trusts announce class of cancer research scholars
Steven Bangert named CEO of the Year by the American Cancer Society
Breakthrough Therapy designation granted to CTL019 in ALL
European Commission approves Halaven for metastatic breast cancer
Breakthrough Therapy designation granted to blinatumomab in Ph- ALL
Mylan launches generic Carboplatin Injection in multi-dose vials